UHRF1 and cancer: In the Kaplan–Meier analysis, the UHRF1-positive group (n = 40) exhibited significantly poorer overall survival (OS) and cancer-specific survival (CSS) than the UHRF1-negative group (n = 120) (3-year OS rate 51.4% vs. 81.0%, log-rank P = 0.0023; 3-year CSS rate 59.1% vs. 85.1%, log-rank P = 0.0057; Figure 4A).